Navigation Links
Euthymics presents phase II data for EB-1010 in major depression at ACNP annual meeting
Date:12/8/2010

Euthymics Bioscience, Inc. today will present Phase II clinical data demonstrating that its lead product candidate EB-1010, a next-generation antidepressant, is effective for treating major depressive disorder (MDD) based on multiple standard measures of outcome for depression. EB-1010 also improved measures of anhedonia, a hallmark symptom of MDD, which is characterized by the inability to experience pleasure. The data further demonstrate that EB-1010 is well tolerated, without the weight gain or sexual dysfunction associated with the most common pharmacological treatments for depression. The data are being presented at the 49th annual meeting of the American College of Neuropsychopharmacology (ACNP) in Miami, Florida.

Euthymics' EB-1010 is a novel unbalanced triple reuptake inhibitor antidepressant intended for patients with MDD who do not respond adequately to selective serotonin reuptake inhibitors (SSRIs), a class which comprises the most common medications in the antidepressant market, which is currently valued at nearly $20 billion worldwide, according to IMS. However, a large subset of patients with major depression - about 66% - do not experience remission after an adequate initial treatment with SSRIs, according to the STAR*D study, a large seven-year study sponsored by the National Institutes of Mental Health. STAR*D also showed that outcomes improved when patients were treated with multiple medications to modulate the key monoamines associated with depression, namely, serotonin, norepinephrine and dopamine. EB-1010 replicates this triple profile in a single medication.

"These data represent convincing Phase II proof-of-concept efficacy for EB-1010 in MDD. More importantly, they validate the potential of a unique unbalanced triple reuptake inhibition profile to treat a large segment of MDD patients with significant unmet medical need," said Pierre V. Trn, M.D., Euthymics Chief Medical Officer, and lead author on the presentation. "
'/>"/>

Contact: Jennifer Anderson
janderson@biocompartners.com
212-918-4642
BioCom Partners
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. FAB-HOMES™ Presents First Passive House Collection
2. NOVAVAX Presents Positive Clinical Results at The World Health Organization Conference, Geneva, Switzerland
3. AADR presents honorary membership to Senator Tom Harkin
4. UCLA Health System Presents: How to Successfully Implement a Clinical Portal
5. Refine Dermatique Aesthetic Medical Team Presents Free Educational Event in Otsego, MN
6. CNBC Presents 'Tom Brokaw Reports: BOOMER$!' on Thursday, March 4th at 9PM ET/PT
7. Fifth Anniversary of Global Tobacco Control Treaty Presents Opportunity For U.S. Ratification and Leadership
8. CareTech Solutions Presents Specialized Healthcare Call Center at HIMSS10
9. Morehead Presents Webinar on "When Satisfaction Isn't Enough: Improving RN Engagement"
10. Targeting leukemia cells gene addiction presents new strategy for treatment
11. Keynote Speaker Presents Top Business Plan For Internal Communication Through Social Media
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... (PRWEB) January 22, 2015 The Incredible Bulk ... Ben Pakulski to increase lean muscle by up to 30lbs ... caught the attention of HealthyandFitZone.com’s Stan Stevenson, prompting an investigative ... it is a step-by-step, scientific diet formula that allows the ...
(Date:1/22/2015)... 2015 The federal court overseeing thousands of ... Court, Southern District of West Virginia has upheld a $2 ... first bellwether trial. In an Order dated January 21st, the ... finding that C.R. Bard had not proven a miscarriage of ...
(Date:1/22/2015)... released a new blog post explaining the main features of ... Auto insurance quotes help many drivers find the best coverage ... an agent or visit an agency for price information. These ... http://autocarinsurancebest.com/ . , Every business who relies heavily on transportation ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 A ... Sports Medicine flagship journal Medicine & Science in ... before exercise may help reduce gastrointestinal (GI) problems ... , Participants in the double-blind, placebo-controlled study ...
(Date:1/22/2015)... Four years since the release of their debut recording Love is ... Avasa & Matthew Love – the duo are pleased to announce ... White Swan Records on February 24, 2015. , THE ROAD offers ... to all of us to walk out of the mire of ...
Breaking Medicine News(10 mins):Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4
... breast cancer researcher and assistant member at Moffitt ... General Electric,s $100 million healthymagination Challenge to develop ... to determine if they are predisposed to develop ... grant awarding initiative focuses on "finding new ideas ...
... Researchers at Moffitt Cancer Center and colleagues have ... strong concerns about their ability to have children ... health-related quality-of-life survey tools used to elicit answers ... these concerns. Parents, who often answer survey questions ...
... Center have placed new emphasis on gathering data on cancer ... focus is on gathering and using that data to develop ... treatment and for cancer survivors. Much of the quality ... in Moffitt,s Department of Health Outcomes & Behavior. "Among ...
... , FRIDAY, April 27 (HealthDay News) -- People with chronic ... be able to sleep better, according to a new study. ... basis. The study included 214 people with chronic jaw ... patients were white females, whose average age was 34. ...
... April 27 (HealthDay News) -- People undergoing outpatient surgery should ... to a new study that finds the risk is higher ... older or obese. The University of Michigan researchers found ... clot after outpatient surgery. More than 60 percent of ...
... and Rebecca Moores Professor of Psychology, has earned the ... symbol of overall career excellence and the highest honor ... carries a cash prize of $10,000. "The Farfel ... that we may have as professionals, as mentors, teachers, ...
Cached Medicine News:Health News:Moffitt researcher awarded GE grant to develop tool to detect breast cancer metastasis genetic risks 2Health News:Moffitt researchers find adolescents with cancer concerned about their future reproductive health 2Health News:Moffitt researchers find adolescents with cancer concerned about their future reproductive health 3Health News:Moffitt Cancer Center researchers: Quality of life as important as quantity of life 2Health News:Moffitt Cancer Center researchers: Quality of life as important as quantity of life 3Health News:Adjusting Your Attitude About Chronic Pain May Help You Sleep 2Health News:Blood Clot Risk for Outpatients Needs More Attention: Study 2Health News:Neuropsychologist receives University of Houston's highest faculty honor 2Health News:Neuropsychologist receives University of Houston's highest faculty honor 3
(Date:1/23/2015)... 2015  iMD Companies, Inc. (ICBU) has repositioned itself as a ... grab a foothold in the hydroponic, hemp and medical marijuana ... presence in the sector, and recently partnering with the Chippewa ... and medical marijuana, iMD is committing to bring its vision ...
(Date:1/23/2015)...  Mallinckrodt plc (NYSE: MNK ) announced today ... repurchase program. The open-ended authorization permits the company to ... shares. "Funding additional initiatives and seeking ... continue to pursue a range of focused growth strategies," ...
(Date:1/22/2015)... 22, 2015  BiOptix is pleased to announce the appointment ... of Chemistry and Biochemistry. Scott joins the company after previous ... Amgen throughout the course of his nearly 20 year ... is a nationally recognized thought leader in the biosensor ...
Breaking Medicine Technology:iMD Companies Poised to Make Impact in Multi-Billion Dollar Medical Marijuana Sector With Recent Investments and Strategic Partnerships 2Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2
... BETHESDA, Md., April 14 Micromet, Inc.,(Nasdaq: ... novel, proprietary,antibodies for the treatment of cancer, ... meeting of the American Association for,Cancer Research ... that commercial,anti-cancer antibodies trastuzumab (Herceptin(R); Genentech, Roche),cetuximab ...
... the, Tumor Suppressor P53 Inhibited Tumor Growth Synergistically in Preclinical ... ... 14 ,Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) announced today that ... 2008 Annual Meeting of the American Association for Cancer Research,(AACR) further ...
Cached Medicine Technology:Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies 2Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies 3Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies 4Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies 5Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrine's anti-PS Vascular Targeting Antibodies 2Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrine's anti-PS Vascular Targeting Antibodies 3Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrine's anti-PS Vascular Targeting Antibodies 4
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: